ATE500277T1 - Hybridpeptide für die behandlung von bacteraemie und sepsis - Google Patents

Hybridpeptide für die behandlung von bacteraemie und sepsis

Info

Publication number
ATE500277T1
ATE500277T1 AT02715695T AT02715695T ATE500277T1 AT E500277 T1 ATE500277 T1 AT E500277T1 AT 02715695 T AT02715695 T AT 02715695T AT 02715695 T AT02715695 T AT 02715695T AT E500277 T1 ATE500277 T1 AT E500277T1
Authority
AT
Austria
Prior art keywords
bacteremia
treatment
sepsis
hybrid peptides
peptides
Prior art date
Application number
AT02715695T
Other languages
English (en)
Inventor
Itzhak Ofek
Matityahu Fridkin
Haim Tsubery
Original Assignee
Univ Ramot
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ramot, Yeda Res & Dev filed Critical Univ Ramot
Application granted granted Critical
Publication of ATE500277T1 publication Critical patent/ATE500277T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • C07K7/62—Polymyxins; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02715695T 2001-01-16 2002-01-16 Hybridpeptide für die behandlung von bacteraemie und sepsis ATE500277T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26121201P 2001-01-16 2001-01-16
PCT/IL2002/000038 WO2002055543A2 (en) 2001-01-16 2002-01-16 Hybrid peptides for treatment of bacteremia and septicemia

Publications (1)

Publication Number Publication Date
ATE500277T1 true ATE500277T1 (de) 2011-03-15

Family

ID=22992355

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02715695T ATE500277T1 (de) 2001-01-16 2002-01-16 Hybridpeptide für die behandlung von bacteraemie und sepsis

Country Status (7)

Country Link
US (1) US7435716B2 (de)
EP (1) EP1351992B1 (de)
AT (1) ATE500277T1 (de)
CA (1) CA2444637A1 (de)
DE (1) DE60239316D1 (de)
IL (1) IL156942A0 (de)
WO (1) WO2002055543A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8038984B2 (en) * 1998-06-20 2011-10-18 Washington University Membrane-permeant peptide complexes for treatment of sepsis
US6951652B2 (en) * 1998-07-29 2005-10-04 Biosynth S.R.L. Vaccine for prevention of gram-negative bacterial infections and endotoxin related diseases
WO2004033482A2 (en) 2002-10-08 2004-04-22 Genencor International, Inc. Phenolic binding peptides
US7272373B2 (en) * 2004-06-30 2007-09-18 Silacon Laboratories Inc. Ratiometric clock systems for integrated receivers and associated methods
US20060004185A1 (en) * 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
EP2035041B1 (de) 2006-06-30 2020-01-08 Syntab Therapeutics GmbH Konjugate für die immanente immuntherapie bei krebs
PT2057185E (pt) 2006-08-11 2016-06-17 Northern Antibiotics Oy Derivados de polimixina e suas utilizações
US7807637B2 (en) * 2006-08-11 2010-10-05 Northern Antibiotics Oy Polymyxin derivatives and uses thereof
FI20085469A0 (fi) 2008-02-08 2008-05-16 Northern Antibiotics Oy Polymyksiinijohdannaiset, joissa on lyhyt rasvahappohäntä, ja niiden käyttöjä
US8193148B2 (en) * 2008-02-08 2012-06-05 Northern Antibiotics Ltd. Short fatty acid tail polymyxin derivatives and uses thereof
US8329645B2 (en) * 2008-02-08 2012-12-11 Northern Antibiotics Ltd. Polymyxin derivatives and uses thereof
US9096649B2 (en) 2008-02-08 2015-08-04 Northern Antibiotics Ltd. Polymyxin derivatives and uses thereof
AR074874A1 (es) 2008-12-23 2011-02-16 Biosource Pharm Inc Composiciones antibioticas para el tratamiento de infecciones gram negativas. metodo. uso. compuesto.
EP2415780A4 (de) * 2009-03-30 2012-10-10 Hebei Yuansen Pharmaceutical Co Ltd Synthetisches peptid und verwendungen davon
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
GB201609083D0 (en) 2016-05-24 2016-07-06 Syntab Therapeutics Gmbh Synthetic compound
HRP20220479T1 (hr) 2016-06-01 2022-05-27 Athira Pharma, Inc. Spojevi
WO2019085926A1 (zh) * 2017-10-31 2019-05-09 上海医药工业研究院 多黏菌素类似物及其制备方法
CN111527100A (zh) * 2017-11-02 2020-08-11 昆士兰大学 肽类抗生素
CN110669107B (zh) * 2018-07-02 2024-04-02 上海医药工业研究院 抗菌肽及其制备方法
WO2021195716A1 (en) * 2020-04-02 2021-10-07 Monash University Antibiotic conjugates

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3104388A1 (de) 1981-02-07 1982-10-21 Basf Ag, 6700 Ludwigshafen Verfahren zur herstellung von 1-alkyl-2-chlor-5-nitro-4-benzol-sulfonsaeuren
US4427660A (en) * 1982-03-03 1984-01-24 Research Corporation Formyl-methionyl chemotatic peptide antibiotic conjugates useful in treating infections
US5484885A (en) * 1989-07-05 1996-01-16 Emory University Chemotactic, antibiotic and lipopolysaccharide-binding peptide fragments of CAP37
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US5780429A (en) * 1995-12-22 1998-07-14 Marine Biological Laboratory Anti-LPS factor from horseshoe crabs and methods of use
US5925659A (en) * 1996-05-07 1999-07-20 Merck & Co., Inc. Antibacterial agents
US6861067B2 (en) * 1998-09-17 2005-03-01 Sherwood Services Ag Hydrogel wound dressing and the method of making and using the same
US6733997B1 (en) * 1998-10-30 2004-05-11 National University Of Singapore Isolated nucleic acids encoding a secretory signal for expression and secretion of heterologous recombinant proteins
AU2001261189A1 (en) * 2000-05-03 2001-11-12 Tularik, Inc. Pyrazole antimicrobial agents

Also Published As

Publication number Publication date
WO2002055543A3 (en) 2003-02-06
EP1351992B1 (de) 2011-03-02
CA2444637A1 (en) 2002-07-18
DE60239316D1 (de) 2011-04-14
EP1351992A2 (de) 2003-10-15
WO2002055543A2 (en) 2002-07-18
US7435716B2 (en) 2008-10-14
US20040082505A1 (en) 2004-04-29
IL156942A0 (en) 2004-02-08

Similar Documents

Publication Publication Date Title
DE60239316D1 (de) Hybridpeptide für die behandlung von bacteraemie und sepsis
DE69940371D1 (de) Beta-glucan enthaltende zusammenstellungen und spezifische immunoglobuline
UA85993C2 (ru) Конъюгат, который содержит бактериальный суперантиген и антительную составную, фармацевтическая композиция, которая его содержит, и способ лечения рака у млекопитающего
TR200201484T2 (tr) Çeşitli hastalıkların koruyucu ve iyileştirici tedavisi için bakteriyel fajlar ile ilişkili lisleme enzimlerinin kullanımı
TR200102497T2 (tr) Yeni streptococcus antijenleri
MXPA03005273A (es) Anticuerpos producidos procarioticamente y sus usos.
DE69928952D1 (de) Chinolin-derivate und ihre verwendung als antibakterielle wirkstoffe
IT1270123B (it) Composizioni farmaceutiche contenenti microorganismi ingegnerizzati e loro uso per terapia
MXPA02000119A (es) Elementos mezcladores estaticos apilados.
DE69713151D1 (de) Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung
PL365246A1 (en) Lactic acid bacteria capable of reducing an individual's tendency to develop allergic reactions
ATE556092T1 (de) Mittel zur diagnose und therapie von ctcl
DE60331849D1 (de) Antibakterielle wirkstoffe
ATE543831T1 (de) Antibakterielle wirkstoffe enthaltende konjugate von glykopeptiden und membranassoziierenden peptiden
ATE258057T1 (de) Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen
CA2388910A1 (en) Antimicrobial activity of the first cationic cluster of human lactoferrin
DE3780644D1 (de) Glykopeptid-antibiotika.
TR199900661T2 (xx) Cilt enfeksiyonlar�n�n tedavisi amac�yla 1-hidroksi-2-piridonlar�n kullan�m�
DE69828063D1 (de) Menschliche defensin def-x, gen und cdna, deren enthaltende zusammensetzungen und deren diagnostische und therapeutische anwendungen
ATE182470T1 (de) Multimeres alpha-lactalbumin enthaltende antibakterielle zusammensetzung
Wilson Bacterial adhesion to host tissues: mechanisms and consequences
WO2000002913B1 (en) Chemotaxis-inhibiting protein of staphylococcus (chips) and its use
DE50113974D1 (de) Kombinationspräparate von 3-n-formylhydroxylaminopropylphosphonsäurederivaten oder 3-n-acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen
DE69634917D1 (de) Milchsäurebakterien und ihre anwendung zur herstellung von hypercholesterolemische aktive produkte
GEP20032929B (en) 6-O-Methyl-Erythromycin A Class, Novel 8a-and 9a-15-Membered Lactams, Method for Their Production and Pharmaceutical Composition for Treatment of Bacterial Infections

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties